These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38750391)

  • 21. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
    Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
    Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
    Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
    Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.
    Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B
    Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents.
    Mueller L; Barrow P; Jacobsen B; Ebeling M; Weinbauer G
    Reprod Toxicol; 2023 Jun; 118():108360. PubMed ID: 36894038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy.
    Babić M; Banović M; Berečić I; Banić T; Babić Leko M; Ulamec M; Junaković A; Kopić J; Sertić J; Barišić N; Šimić G
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model.
    Wang J; Bai J; OuYang S; Wang H; Jin Y; Peng X; Ge X; Jiao H; Zou J; He C; Xiao P; Song F; Qu Y
    Hum Mol Genet; 2022 May; 31(10):1635-1650. PubMed ID: 34888619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
    Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
    Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splicing of the Survival Motor Neuron genes and implications for treatment of SMA.
    Bebee TW; Gladman JT; Chandler DS
    Front Biosci (Landmark Ed); 2010 Jun; 15(3):1191-1204. PubMed ID: 20515750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
    Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance.
    Keinath MC; Prior DE; Prior TW
    Appl Clin Genet; 2021; 14():11-25. PubMed ID: 33531827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
    Singh RN; Ottesen EW; Singh NN
    Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
    Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
    BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
    Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III.
    Zheleznyakova GY; Kiselev AV; Vakharlovsky VG; Rask-Andersen M; Chavan R; Egorova AA; Schiöth HB; Baranov VS
    BMC Med Genet; 2011 Jul; 12():96. PubMed ID: 21762474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
    Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
    Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.